WHO WE ARE


Alvotech is a privately owned biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets. We are specialists in biotechnology all working towards a common goal: to be a global leader in the biosimilar space and to deliver high quality cost competitive products and services to our partners and to patients worldwide.

We come from all around the world, bringing many years of combined knowledge and expertise. Our multicultural environment is unique and inclusive.

million investment
500
mAbs in pipeline
7

Company

CEO message

Alvotech was founded in 2013, with the mission to create a company focused on being a pure biosimilar player and specializing in the development and manufacturing of biosimilar monoclonal antibodies for global markets. 

Learn more

Milestones

Our growth story

Alvotech was founded in 2013 by the Chairman and CEO of Alvogen, Robert Wessman. Shortly after its creation, Alvotech announced its strategy to invest in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies ...

Learn more

WHAT WE DO


We are focused on developing and bringing to market highest quality biosimilars. Our current pipeline consists of seven biosimilar monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases.

These products are developed in our four Research & Development centers located across Europe and will be manufactured in our state-of-the-art facility located in Reykjavik Iceland.

We develop, produce and release our biosimilars in house with the latest availabletechnology and to the highest quality standards for the supply of finished and ready to commercialize products to our partners worldwide.

Meet managment

LEADERSHIP TEAM

Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.

Meet management

Strategy

Five key elements

Our strategy is focused on 5 key pillars, incorporated in our culture and in our dailywork. First one is the development of a relevant portfolio of biosimilar mAbs through our fully integrated R&D organization and facilities ...

Learn more

Meet us at .
Please tell us a little about yourself.

Meet Us